The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world (RW) characteristics and outcomes in platinum-resistant ovarian cancer (PROC) patients treated with mirvetuximab soravtansine (MIRV) monotherapy or single-agent chemotherapy (CTx).
 
John Chan
Consulting or Advisory Role - Abbvie; AstraZeneca; Corcept Therapeutics; Daiichi Sankyo; Eisai; Ethicon; GlaxoSmithKline; moon surgical; Myriad Genetics; Pfizer
Speakers' Bureau - Abbvie; AstraZeneca; Eisai; GlaxoSmithKline; Merck; Myriad Genetics; Pfizer; Pfizer
Research Funding - Abbvie (Inst); Corcept Therapeutics (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Corcept Therapeutics; Eisai; GlaxoSmithKline; Merck; Myriad Genetics; Pfizer
 
Natalie Ayoub
No Relationships to Disclose
 
Carmen Chen
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Rajesh Kamalakar
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Zahra Majd
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Dana Chase
Honoraria - AstraZeneca/Merck; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca/Merck; Corcept Therapeutics; Daiichi Sankyo/Astra Zeneca; Genmab; Tesaro/GSK
Speakers' Bureau - Abbvie; AstraZeneca/Merck; Eisai; Myriad Genetics; Pfizer; Tesaro/GSK
Research Funding - GlaxoSmithKline (Inst); Merck
Travel, Accommodations, Expenses - GlaxoSmithKline